CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is pleased to announce positive 12-week interim results from the ongoing multi-dose Phase II trial of Ruxoprubart, a novel complement-targeting ...

While the detailed molecular mechanisms underlying these surprising clinical ... CKD is still one of the strongest predictors of a poor prognosis in patients with both ANCA- associated vasculitis (AAV ...

The interferon gamma signaling pathway may be a common feature in the pathophysiology of various forms of ANCA-associated vasculitis. This study received financial support from multiple ...

MANCHESTER, England — A soon-to-be-released guidance from the British Society for Rheumatology on the management of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV ...

The global market for ANCA-associated vasculitis (ANCA-V) treatments has been expanding steadily, driven by advancements in treatment options, growing disease awareness, and the development of ...

Higher relapse rates were associated with c-ANCA/PR3 positivity and granulomatosis with polyangiitis phenotype. In a retrospective study of patients with antineutrophil cytoplasmic (ANCA ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

Vasculitis is a family of 15-20 rare autoimmune diseases It occurs when the body%27s own immune system attacks the body%27s blood vessels For a minority of people with vasculitis%2C it can be ...

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.